TNFRSF25-MEDIATED TREATMENTS OF IMMUNE DISEASES AND DISORDERS

Contacts

Contact University of Alberta

Inventors
  • SEAVEY, Matthew
  • HUTCHINS, Jeff
  • JASUJA, Rahul
  • SHAPIRO, .M
  • MARFIL-GARZA, Braulio
Documents
Applicants
  • PELICAN THERAPEUTICS
  • University of Alberta

Abstract

The present disclosure is directed to a method of treating or preventing diabetes, prediabetes, and/or glucose intolerance using TNF Receptor Superfamily Member 25 (TNFRSF25) agonistic antibody or antigen binding fragment thereof. The disclosure is also directed to methods for increasing graft survival and for treating or preventing graft-versus-host disease (GVHD) using TNFRSF25 agonistic antibody.